BridgeMD
New treatment option for Lung Cancer
Official title Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
ClinicalTrials.gov ID: NCT06481813
What this study is testing
- What it's testing
- In clinical trials, patients are selected according to strict eligibility criteria (inclusion and exclusion criteria). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Patients :
- Adult
- Patient newly diagnosed with NSCLC or CPC
- Cared for at Nantes University Hospital
- Affiliated or beneficiaries of a social security scheme or similar
You likely can't join if
- Patients :
- Previous anticancer treatment for Lung cancer
- Patients who have not consented to participate in the BREATHE collection
- History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
- Inclusion in a therapeutic trial with blinded treatment
- Patients under guardianship
See the full eligibility criteria
- Patients :
- Adult
- Patient newly diagnosed with NSCLC or CPC
- Cared for at Nantes University Hospital
- Affiliated or beneficiaries of a social security scheme or similar
- Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the...
- Having agreed to participate in this study by signing the biocollection consent. Healthy people :
- Adult
- Affiliated or beneficiaries of a social security or similar scheme
- Who have agreed to participate in this study by signing the Biocollection consent form.
- No known infectious pathology
- No known history of cancer
- No known history of chronic autoimmune disease
- No background immuno-suppressive treatment Ancillary Study : -Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in...
- Patients :
- Previous anticancer treatment for Lung cancer
- Patients who have not consented to participate in the BREATHE collection
- History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
- Inclusion in a therapeutic trial with blinded treatment
- Patients under guardianship
- Patients with AME.
- Pregnant or breast-feeding women Healthy people :
- Person under guardianship
- Person benefiting from AME (State medical aid)
- Pregnant or breast-feeding women Ancillary Study : \- Pregnant or breast-feeding women
The study team makes the final eligibility decision.
Where it's taking place
- Nantes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nantes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.